不同型号血细胞分离机对献血者细胞参数与机采血小板采集效率比较

目的比较不同型号血细胞分离机对献血者细胞参数与机采血小板采集效率。方法选取2018年1月至2019年11月我站的318例献血者,其中159名献血者应用AmiCORE、MCS+及Trima血细胞分离机捐献双份血小板,平均分为3组,另外159名献血者应用AmiCORE、MCS+及Trima血细胞分离机捐献单份血小板,平均分为3组。比较三组的单份及双份血小板细胞参数不合格率及分离机性能。结果MCS+组单份血小板细胞参数不合格率低于AmiCORE组和Trima组,差异具有统计学意义(P<0.05)。MCS+组单份血小板采集效率及时间高于AmiCORE组及Trima组,差异具有统计学意义(P<0.05);Trima组抗凝剂使用量及全血处理量多于MCS+组及AmiCORE组(P<0.05)。三组双份血小板细胞参数不合格率比较,差异均无统计学意义(P>0.05)。MCS+组双份血小板采集效率高于AmiCORE组及Trima组,差异具有统计学意义(P<0.05);AmiCORE组采集时间长于MCS+及Trima组,Trima组抗凝剂使用量及全血处理量多于MCS+及AmiCORE组,差异具有统计学意义(P<0.05)。结论AmiCORE、MCS+及Trima血细胞分离机对产品采集具有较高采集效率,符合国家有关标准,血液制备和采集过程可供,各机型血小板细胞参数不合格率、血小板分离机性能存在区别。血液制备及血液采集过程具有可控性,应依据献血者自身特点选择不同血细胞分离机。     

机采血小板献血者外周血血液学参数的观察

目的观察机采血小板献血者外周血血液学参数的变化。方法从机采血小板献血者中选取23名12个月内机采血小板量为4～10个治疗量的献血者作为观察组(平均每个治疗量血小板计数≥2.5×1011个),于末次机采血小板前检测外周血白细胞(WBC)、红细胞(RBC)、血红蛋白(Hb)、血细胞比容(HCT)、血小板(PLT)、平均血小板体积(MPV)、血小板分布宽度(PDW)、大血小板比例(P-LCR),与40名健康对照者进行比较,将所得数据进行统计学分析。结果观察组外周血WBC、RBC、Hb、HCT与对照组相比,差异无显著性(P>0.05)。观察组外周血PLT显著高于对照组(P<0.01),而MPV、PDW、P-LCR均显著低于对照组(P<0.01)。MPV与PLT呈中度负相关,MPV与PDW、P-LCR呈显著正相关。结论为机采血小板献血者查体时要结合PLT、MPV、PDW、P-LCR等血液学参数,综合考虑献血者机体的功能状况。     

多次捐献机采血小板献血者的血小板四项参数变化情况探讨

目的 探讨24个月内献血者捐献机采血小板的频率与献血员外周血小板四项参数的变化情况的相关性.方法 从捐献机采血小板献血者中选取69名24个月内捐献机采血小板量为6～28个治疗量的献血者作为观察组(平均每个治疗量血小板计数≥2.5×1011个),采集献血员末次捐献机采血小板前的静脉血;选取71名未捐献过机采血小板的健康无偿献血员作为对照组,采集献血员全血样本.检测血小板(PLT)、平均血小板体积(MPV)、血小板分布宽度(PDW)、大血小板比例(PLCR).比较两者血小板四项参数结果,将所得数据进行统计学分析.结果 观察组外周血PLT、MPV、PDW与对照组相比,差异均无显著性(P＞0.05).而P-LCR显著低于对照组(P＜0.05).结论 为机采血小板献血者体检时要结合PLT、MPV、PDW、P-LCR等血液学参数,综合考虑献血者机体的功能状况.     

肝病患者外周血小板四项参数观察

采用ＭＥＴ－ＨＣ２０２２型血细胞仪对９０例肝病患者血小板四项参数进行检测，发现肝病患者血小板，血小板平均体积及血小板压积均显著降低，提示血小板参数测定对肝病患者血小板数量和形态变化，病情判断有一定的参考价值。     

糖尿病患者血小板4项参数与血管病变探讨

目的探讨糖尿病患者血小板参数变化及其临床意义。方法使用XE-2100型全自动血细胞分析仪分别测定健康对照、糖尿病和冠心病患者血小板计数（PLT）、血小板平均体积（MPV）、血小板分布宽度（PDW）及血小板比容（PCT）。结果与对照组比较,2型糖尿病有血管病变组和冠心病组的PLT、MPV、PDW差异有统计学意义（P〈0．01）,PCT差异无统计学意义（P〉0．05）;2型糖尿病无血管病变组血小板4项参数差异无统计学意义（P〉0．05）。结论血小板参数的变化在糖尿病血管病变发生、发展中有重要作用,对临床研究糖尿病并发症有较大参考价值。     

急性白血病患者血小板参数变化及临床意义

目的研究急性白血病患者血小板计数(PLT)、血小板平均体积(MPV)、血小板体积分布宽度(PDW)及血小板压积(PCT)的临床意义。方法用拜耳ADVIAl20全自动血细胞分析仪测定50例急性白血病(AL)患者初诊期、骨髓象缓解期及40例正常人的血小板参数PLT、MPV、PDW、PCT。结果初诊AL患者PLT、MPV、PCT均显著低于对照组(P<0.001),但PDW与对照组比较无显著性差异(P>0.05)。初诊AL患者PLT、PDW、PCT均显著低于骨髓象缓解组(分别为P<0.001、P<0.05、P<0.001),但MPV与骨髓象缓解组比较无显著性差异(P>0.05)。骨髓象缓解组PLT、PDW均显著高于对照组(P<0.001),MPV显著低于对照组(P<0.001),PCT与对照组比较无显著性差异(P>0.05)。结论血小板四项参数的测定对预示急性白血病病程进展以及反映骨髓造血功能恢复有重要的意义。     

血小板参数在血小板减少性疾病中的应用

目的 探讨血常规检测中血小板计数(PLT)及相关参数[血小板平均体积(MPV)、血小板分布宽度(PDW)、大血小板比率(P-LCR)、血小板压积(PCT)]对血小板减少性疾病的诊断价值及疗效观察,为临床诊治提供指导意义.方法 选取四类血小板减少患者115例,其中特发性血小板减少性紫癜(ITP) 71例,再生障碍性贫血(AA)29例,骨髓增生异常综合征(MDS)15例,采用Sysmex XE-5000全自动血细胞分析仪检测PLT、MPV、PDW、P-LCR、PCT,并与健康者及治疗前后对比.结果 初诊时ITP组PLT、PCT明显低于健康对照组(P<0.01),MPV、PDW、P-LCR明显高于健康对照组(P<0.01);AA组PLT、PCT、MPV、P-LCR明显低于健康对照组(P<0.01),PDW差异无统计学意义(P>0.05);MDS组PLT、PCT明显低于健康对照组(P<0.01),PDW明显高于健康对照组(P<0.01),MPV、P-LCR差异无统计学意义(P>0.05).ITP初诊时与治疗后缓解组比较,PLT、PCT明显升高(P<0.01),MPV、PDW、P-LCR明显降低(P<0.01).结论 血小板参数的检测对于血小板减少性疾病的疗效观察与预后判断具有重要的临床意义.     

肾综合征出血热中血小板四项参数的动态观察

肾综合征出血热 (ＨＦＲＳ)从第２病日外周血小板可以下降 ,并可见异型血小板。我们对４２例ＨＦＲＳ动态观察血小板计数 (ＰＬＴ) ,血小板压积 (ＰＣＴ) ,血小板平均体积(ＭＰＶ) ,血小板分布宽度 (ＰＤＷ) ,旨在了解ＨＦＲＳ患者血小板数量、形态和功能。对象与方法１、对象４２例ＨＦＲＳ均系１９９９年８月～２０００年６月住院患者 ,符合１９９７年制订的流行性出血热防治方案诊断标准 ,ＨＦＲＳ抗体阳性。其中男３２例 ,女１２例。年龄２２～６５岁 ,平均 (４０．５１±１４．２７)岁。其中轻型１０例 ,中型１９例 ,重型８例 ,危重型…     

无偿献血者外周红细胞指标对单采血小板质量的影响

目的：探讨无偿献血者外周红细胞指标对单采血小板质量的影响,并探讨筛选献血者的适宜标准。方法：收集194名无偿献血者的献血前外周红细胞指标（包括红细胞平均体积、平均血红蛋白含量、平均血红蛋白浓度）与单采血小板收集量进行单因素相关分析,并对献血者采集前后的相应指标作配对比较。结果：无偿献血者的采血前外周红细胞平均体积、平均血红蛋白含量、平均血红蛋白浓度均与单采血小板收集量呈负相关关系,且有统计学意义。结论：外周红细胞指标是筛选单采血小板无偿献血者的重要指标。     

Pseudothrombocytopenia in plateletpheresis donors

BACKGROUND: EDTA pseudothrombocytopenia (PTCP) is an in vitro artifact in which the anticoagulation of blood with EDTA is associated with in vitro agglutination of platelets, resulting in a spuriously low platelet count. In apheresis donors, whole-blood samples for complete blood counts are routinely drawn into tubes anti-coagulated with EDTA. STUDY DESIGN AND METHODS: Records of apheresis donors were examined to identify persons in whom the postdonation counts were less than 100 × 10(9) per L. Identified donors were studied to confirm the presence of PTCP by drawing blood samples into EDTA, heparin, and trisodium citrate for serial platelet counts at room-temperature incubation. Platelet counts in citrated plasma were measured before and after the addition of EDTA. A single HLA-matched component from an identified PTCP donor was monitored for response by corrected count increment in the recipient. RESULTS: A total of nine donations were identified, involving 2 donors from a population of 945 donors (prevalence 0.2%). On testing, both donors were confirmed to have PTCP. The addition of EDTA to citrated plasma did not affect the platelet count. Response in a recipient to an HLA-matched component showed an acceptable corrected count increment. CONCLUSION: PTCP may occur in plateletpheresis donors and result in needless medical referral or donor deferral. PTCP does not appear to alter the yield content of the component or to be passively transferred to a recipient.     

献血者红细胞CR1分子基因表达与献血后免疫状况相关性研究

目的　研究无偿献血者红细胞CR1基因高中低表达者献血后免疫状况 ,为安全献血提供依据。方法　随机选择 176位无偿献血者血液 ,应用PCR和HindⅢ酶切技术测定CR1基因表达 ;应用酶联免疫吸附法测定红细胞CR1分子数量A40 5值 ,随机抽样调查 33位高表达者及 2 5位中低表达者 ,在献血后 6个月时测定免疫球蛋白、C3 、C4及淋巴细胞亚群 ,并详细询问献血后状况。结果　献血者红细胞CR1高表达者与中低表达者在CR1A40 5值分子数量上存在显著性差异 (t=7.4 0 ,P <0 .0 1) ,但是两者献血后机体一般状况与部分免疫指标检测均无显著性差异(P >0 .0 5 )。结论　红细胞CR1高中低表达的无偿献血者献血后机体的体液与细胞免疫状况无明显变化。     

献血者红细胞CR1分子基因表达与献血后免疫状况相关性研究

目的研究无偿献血者红细胞CR1基因高中低表达者献血后免疫状况,为安全献血提供依据.方法随机选择176位无偿献血者血液,应用PCR和HindⅢ酶切技术测定CR1基因表达;应用酶联免疫吸附法测定红细胞CR1分子数量A405值,随机抽样调查33位高表达者及25位中低表达者,在献血后6个月时测定免疫球蛋白、C3、C4及淋巴细胞亚群,并详细询问献血后状况.结果献血者红细胞CR1高表达者与中低表达者在CR1 A405值分子数量上存在显著性差异(t=7.40,P<0.01),但是两者献血后机体一般状况与部分免疫指标检测均无显著性差异(P>0.05).结论红细胞CR1高中低表达的无偿献血者献血后机体的体液与细胞免疫状况无明显变化.     

Comparison of plateletpheresis using two cell separators and identical donors

For prospective comparison of product yield and volume, collection efficiency, white cell (WBC) and red cell (RBC) contamination, donor acceptability, and staff acceptance, each of 31 donors underwent plateletpheresis on two different cell separators (the Fenwal CS-3000 and the COBE Spectra). The same operator performed the paired procedures and collected all study data. The instruments provided equivalent high-yield platelet products (CS-3000: 5.3 x 10(11); Spectra: 5.7 x 10(11]. Platelet collection efficiency was greater with the Spectra (81%) than with the CS-3000 (57%) (p less than 0.0005). All products contained less than 1 mL of RBCs, but the Spectra products were more likely to contain less than 10(6) WBCs (14/31) than those of the CS-3000 (1/31) (p less than 0.001). In the remaining products, the mean WBC contamination was 1.0 x 10(8) for the CS-3000 and 0.03 x 10(8) for the Spectra (p less than 0.001). More ACD-A anticoagulant was infused with Spectra (463 mL) than with CS-3000 procedures (400 mL) (p = 0.002). Although postdonation ionized calcium (Ca2+) levels and the percentage of decrease in Ca2+ were not significantly different between groups, more Spectra donors experienced symptoms of hypocalcemia (20/31 vs 9/31; p = 0.015). CS-3000 products had lower mean volumes (217 mL) than Spectra collections (300 mL) (p less than 0.0005). Both instruments were accepted well by volunteer donors and the technical staff.     

Switching iron‐deficient whole blood donors to plateletpheresis

BACKGROUND: Iron deficiency is a frequent side effect of whole blood (WB) donation. In contrast, less red blood cell loss and therefore less iron loss results from plateletpheresis. STUDY DESIGN AND METHODS: WB donors presenting a decrease in either hemoglobin (Hb) or ferritin levels were offered to switch to plateletpheresis with or without iron supplementation. We analyzed the effect of this intervention on deferral rates for an insufficient Hb level in 168 donors. Further, we assessed how this intervention affected Hb and ferritin levels, anemia occurrence, and platelet (PLT) concentrate yields in the donors who presented at least four successive times for thrombapheresis. RESULTS: Switching WB donors to repetitive plateletpheresis procedures resulted in an increase of median Hb (+12 g/L, p < 0.001) and ferritin (+15.5 ng/mL, p = 0.002) values. Anemia and deferral rates were reduced by 23% (p = 0.004) and 13% (p < 0.001). Between high‐ and low‐frequency apheresis donors, no significant differences in Hb and ferritin levels were found. Similarly, discrepancies in Hb and ferritin values between donors that adopted iron supplementation and those who did not were insignificant. The median PLT concentrate yield was 5.43 × 10¹¹ PLTs. CONCLUSION: Switching iron‐deficient WB donors to plateletpheresis was an effective intervention that permitted us to correct low Hb and ferritin levels while retaining donors in our pool.     

CMV antibody prevalence and seroincidence in plateletpheresis donors

Objective : To determine the prevalence and seroincidence of CMV seropositivity in plateletpheresis donors of different ages and gender. Methods : CMV antibody serostatus, birthdate, and date of first and most recent donation between the years 1976 and 2006 were retrieved from 222 plateletpheresis donor records at the Johns Hopkins Hospital Donor Center. CMV antibody serostatus was obtained for 183 donors at the most recent donation for which CMV antibody data were available. CMV antibody status and time interval between first and most recent donation were also obtained from 97 repeat plateletpheresis donors who were CMV antibody negative at time of first donation. Results : Overall CMV antibody positivity was 35.5% for 183 donors (mean age = 46.0 years) at time of most recent donation. CMV seropositivity tended to increase with age, being 37.5, 17.9, 37.5, 39.0, and 61.5% for donors aged 20–29 years (n = 8), 30–39 years (n = 39), 40–49 years (n = 64), 50–59 years (n = 59), and 60+ years (n = 13), respectively. Overall CMV seroincidence was 1.6 seroconversions per 100 person years with a rate of 1.4 seroconversions per 100 years for men and 2.3 for women. Conclusion : CMV seroprevalence and seroincidence in this plateletpheresis donor population are relatively low so that a large percentage of donors are likely to be able to provide CMV seronegative platelet components for many years. Our data suggest that targeting groups with lower CMV seroprevalence and seroincidence rates such as young people and possibly men will likely yield the highest percentage of CMV seronegative donors. J. Clin. Apheresis, 2008. © 2008 Wiley‐Liss, Inc.     

连续捐献单采血小板献血者血红蛋白和铁蛋白状况调查及分析

目的 调查连续捐献单采血小板对献血者血红蛋白和铁蛋白的影响.方法 选择2018年3-6月北京市红十字血液中心男性献血者73名(平均献血周期为15.26d),依据5次献血的铁蛋白水平分为第1组(n=21,≥30 μg/L)、第2组(n=23,＜30pug/L)和第3组(n=29,在30 μg/L上下变化),对其连续捐献5...     

Effect of plateletpheresis on complete blood count values using three different cell separator systems in healthy donors.

The aim of this study is to investigate changes of CBC values after plateletpheresis in healthy and volunteer donors by using three different cell separator systems. The platelets were collected from 95 donors using the COBE Spectra, from 87 donors using the Fenwal CS-3000 Plus, and from 83 donors using the Fresenius AS-204. After plateletpheresis, white blood cells (WBC), hemoglobin (HGB), hematocrit (HCT), and platelets (PLT) were decreased significantly. When we used the COBE Spectra, the drop in the values of HGB and HCT was significantly less than for the other devices. It is recommended that hematological parameters should be monitored carefully in donors who are supposed to undergo long-term regular apheresis, and to prevent the occurrence of an artificial anemia, which is likely to happen. Selection of cell separator systems should be based on this possibility.     

Study of iron stores in regular plateletpheresis donors

summary . Plateletpheresis donors will lose up to 100 mL of blood at each donation, leading to concern that they may become iron deficient, particularly if donating at the maximum allowed frequency under National Blood Service policy of every 2 weeks. The serum ferritin levels of 508 regular plateletpheresis donors and 101 non-donors were measured to indicate the level of their iron stores. About 33·9% (156/460) of platelet donors had depleted iron stores compared with 3·1% (3/97) non-donors. Results for male and post-menopausal female donors were similar with 36·2% (131/362) of males and 37·7% (20/53) of post-menopausal females showing iron depletion. There was clear correlation with donation frequency in males with 63·9% (46/72) of males donating at 2 weekly intervals found to be iron depleted. The percentage of iron depleted male subjects decreased as donation intervals increased. Correlation with lifetime donations of platelets was not demonstrated, although no donor who had given fewer than 14 blood and/or platelet donations was found to be iron depleted. In males there was a clear correlation between iron depletion and frequency of donation. There appeared to be no correlation with lifetime number of platelet donations. As a result of this study, we have advised that volunteers should not donate platelets more than 15 times per year, so that red cell loss is no more than the equivalent of three whole blood donations (1500 mL).